192 related articles for article (PubMed ID: 17016779)
21. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
22. Forodesine in the treatment of cutaneous T-cell lymphoma.
Lewis DJ; Duvic M
Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
[TBL] [Abstract][Full Text] [Related]
23. The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
Deves C; de Assunção TM; Ducati RG; Campos MM; Basso LA; Santos DS; Batista EL
Bone; 2013 Jan; 52(1):167-75. PubMed ID: 23026564
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative activity of purine nucleoside phosphorylase multisubstrate analogue inhibitors containing difluoromethylene phosphonic acid against leukaemia and lymphoma cells.
Glavas-Obrovac L; Suver M; Hikishima S; Hashimoto M; Yokomatsu T; Magnowska L; Bzowska A
Chem Biol Drug Des; 2010 Apr; 75(4):392-9. PubMed ID: 20102369
[TBL] [Abstract][Full Text] [Related]
25. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.
Balakrishnan K; Verma D; O'Brien S; Kilpatrick JM; Chen Y; Tyler BF; Bickel S; Bantia S; Keating MJ; Kantarjian H; Gandhi V; Ravandi F
Blood; 2010 Aug; 116(6):886-92. PubMed ID: 20427701
[TBL] [Abstract][Full Text] [Related]
26. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
Balakrishnan K; Burger JA; Quiroga MP; Henneberg M; Ayres ML; Wierda WG; Gandhi V
Blood; 2010 Aug; 116(7):1083-91. PubMed ID: 20442367
[TBL] [Abstract][Full Text] [Related]
27. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
28. Novel agents in development for peripheral T-cell lymphoma.
O'Connor OA
Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
[TBL] [Abstract][Full Text] [Related]
29. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
30. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
31. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
32. Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase.
Evans GB; Furneaux RH; Lewandowicz A; Schramm VL; Tyler PC
J Med Chem; 2003 Jul; 46(15):3412-23. PubMed ID: 12852771
[TBL] [Abstract][Full Text] [Related]
33. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
[TBL] [Abstract][Full Text] [Related]
34. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
[TBL] [Abstract][Full Text] [Related]
35. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
36. Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents.
Schramm VL
Biochim Biophys Acta; 2002 Jul; 1587(2-3):107-17. PubMed ID: 12084452
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan.
Tobinai K
Semin Hematol; 2010 Apr; 47 Suppl 1():S5-7. PubMed ID: 20359583
[TBL] [Abstract][Full Text] [Related]
38. New catalytic mechanism for human purine nucleoside phosphorylase.
Canduri F; Fadel V; Basso LA; Palma MS; Santos DS; de Azevedo WF
Biochem Biophys Res Commun; 2005 Feb; 327(3):646-9. PubMed ID: 15649395
[TBL] [Abstract][Full Text] [Related]
39. Structure of human PNP complexed with ligands.
Canduri F; Silva RG; dos Santos DM; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2005 Jul; 61(Pt 7):856-62. PubMed ID: 15983407
[TBL] [Abstract][Full Text] [Related]
40. Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase.
Chen Y; Li Y; Gao J; Yu Q; Zhang Y; Zhang J
Eur J Med Chem; 2024 May; 271():116437. PubMed ID: 38701712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]